

<b>STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2016</b>						
Particulars	3 months ended			9 months ended		Year ended
	31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015	31.03.2016
	Unaudited			Unaudited		Audited
1. Income from Operations						
(a) Net Sales/Income from Operations (Net of Excise Duty)	6,454	7,638	7,202	22,615	20,572	27,454
(b) Other Operating Income	199	222	115	641	330	478
Total Income from Operations (Net)	6,653	7,860	7,317	23,256	20,902	27,932
2. Expenses						
(a) Cost of Materials Consumed	1,119	1,320	1,611	4,473	4,716	6,025
(b) Purchases of Stock-in-Trade	1,239	1,560	741	4,585	2,400	3,360
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(191)	(44)	(74)	(985)	(216)	(241)
(d) Employee Benefits Expense	1,971	1,863	2,017	5,653	5,591	7,413
(e) Depreciation and Amortisation Expense	326	239	247	833	764	1,015
(f) Other Expenses	2,048	2,494	2,257	7,119	6,563	9,027
Total Expenses	6,512	7,432	6,799	21,678	19,818	26,599
3. Profit from Operations before Other Income, Finance Costs and Exceptional Items	141	428	518	1,578	1,084	1,333
4. Other Income	11	18	4	47	77	78
5. Profit from Ordinary Activities before Finance Costs and Exceptional Items	152	446	522	1,625	1,161	1,411
6. Finance Costs	97	18	55	155	224	249
7. Profit from Ordinary Activities after Finance Costs but before Exceptional Items	55	428	467	1,470	937	1,162
8. Exceptional Items - Profit on sale of Biotech Business Unit [Refer Note 4]	-	738	-	738	-	-
9. Profit from Ordinary Activities before Tax	55	1,166	467	2,208	937	1,162
10. Tax Expense						
a. Current Tax	12	250	100	475	197	224
b. MAT Credit Entitlement	(12)	(250)	(100)	(475)	(197)	(224)
c. Deferred Tax	-	141	-	141	-	-
11. Net Profit for the period	55	1,025	467	2,067	937	1,162
12. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323
13. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)						12,036
14. Earnings per Share (of Rs. 8 each) (not annualised):						
(a) Basic	0.33	6.20	2.82	12.50	5.67	7.03
(b) Diluted	0.33	6.20	2.82	12.50	5.67	7.03

**Notes:**

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meetings held on 1<sup>st</sup> February, 2017.
- The results for the quarter ended 31st December, 2016 have been subjected to limited review by the statutory auditors of the Company.
- The Company is exclusively engaged in the pharmaceuticals segment.
- Pursuant to the approval of the Board of Directors at their meeting held on May 26, 2016, the Company had entered into a Business Transfer Agreement dated May 26, 2016 with Intas Pharmaceuticals Limited for sale of Biotech Business Unit, as a going concern on a slump sale basis, at a consideration of Rs. 2,487 lakhs. The sale consideration had been received on July 6, 2016 (closing date). The gain realised from the aforesaid sale of Biotech Business Unit amounting to Rs. 738 lakhs had been disclosed as an exceptional item in the financial results of the previous quarter. The same has been considered as discontinuing operations in accordance with Accounting Standard - 24 - "Discontinuing Operations" and the requisite information for Biotech Business Unit has been furnished hereunder;

Particulars	3 months ended			9 months ended		Year ended
	31.12.2016	30.09.2016	31.12.2015	31.12.2016	31.12.2015	31.03.2016
	Unaudited			Unaudited		Audited
a) Net Sales	-	-	667	643	1,594	2,437
b) Direct Expenses	-	(7)	547	489	1,553	2,114
c) Profit/(Loss) from ordinary activities before tax	-	7	120	154	41	323
d) Tax Expense (net off MAT Credit Entitlement)	-	-	-	-	-	-
e) Net Profit/(Loss) from ordinary activities after tax (c-d)	-	7	120	154	41	323
f) Profit on sale of Biotech Business Unit	-	738	-	738	-	-
g) Tax Expense [net of MAT credit entitlement] on f) above	-	-	-	-	-	-
h) Profit on sale of Biotech Business Unit (net of tax) (f-g)	-	738	-	738	-	-
i) Net Profit/(Loss) from discontinuing operations (e+h)	-	745	120	892	41	323

- Pursuant to an Asset Purchase Agreement (APA) dated July 27, 2016 for purchase of Trademarks on assignment/perpetual license basis and other assets specified in the said APA from Sun Pharmaceutical Industries Limited (including its subsidiary, Sun Pharma Laboratories Limited) the company has capitalised the aforesaid intangible assets amounting to Rs. 4,273 lakhs on October 21, 2016 (closing date).
- During the quarter ended December 31, 2016, the Company has allotted 2,910 equity shares of Rs. 8 each pursuant to exercise of stock options by an employee under "2005 Employee Stock Option Plan".
- Figures for the prior periods have been regrouped where necessary.

For RPG Life Sciences Limited

CT Renganathan  
Managing Director  
Mumbai, 1<sup>st</sup> February, 2017